Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894525 | 0.83 | HTT (0.47) | HTTSLC1A3SLC1A2SLC1A1POLB | |
| SCHEMBL4457494 | 0.83 | HTT (0.47) | HTTSLC1A3SLC1A2SLC1A1POLB | |
| SCHEMBL489096 | 0.81 | RNPEP (0.43) | SLC1A3SLC1A2ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL1258031 | 0.81 | RNPEP (0.43) | SLC1A3SLC1A2ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL489097 | 0.81 | RNPEP (0.43) | SLC1A3SLC1A2ALDH1A1RNPEPSLC7A5 | |
| SCHEMBL9985082 | 0.73 | CA2 (0.43) | SLC1A3SLC1A2SLC1A1ALDH1A1TSHR | |
| SCHEMBL6889610 | 0.72 | CHRM1 (0.46) | HTTSLC1A3SLC1A2SLC1A1TSHR | |
| SCHEMBL6889603 | 0.72 | CHRM1 (0.46) | HTTSLC1A3SLC1A2SLC1A1TSHR | |
| SCHEMBL8883842 | 0.71 | ALDH1A1 (0.37) | HTTALDH1A1TSHR | |
| SCHEMBL8692002 | 0.71 | ALDH1A1 (0.37) | HTTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637676-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2162442-B1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| CN-1044249-C | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1999-07-21 | — | — | CN | disclosed |
| CN-1134153-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1996-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | HTT 1712/4885SLC1A3 2380/4885SLC1A2 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.